A detailed history of Allworth Financial LP transactions in Arvinas, Inc. stock. As of the latest transaction made, Allworth Financial LP holds 125 shares of ARVN stock, worth $2,385. This represents 0.0% of its overall portfolio holdings.

Number of Shares
125
Previous 125 -0.0%
Holding current value
$2,385
Previous $3,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 23, 2024

SELL
$24.46 - $40.4 $342 - $565
-14 Reduced 10.07%
125 $3,000
Q1 2024

Apr 25, 2024

BUY
$36.38 - $52.31 $400 - $575
11 Added 8.59%
139 $5,000
Q4 2023

Jan 24, 2024

BUY
$14.19 - $42.33 $14 - $42
1 Added 0.79%
128 $5,000
Q3 2023

Oct 31, 2023

BUY
$19.64 - $28.21 $569 - $818
29 Added 29.59%
127 $2,000
Q2 2023

Jul 18, 2023

BUY
$21.73 - $31.43 $1,434 - $2,074
66 Added 206.25%
98 $2,000
Q1 2023

Apr 18, 2023

BUY
$26.15 - $37.26 $836 - $1,192
32 New
32 $0

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.02B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Allworth Financial LP Portfolio

Follow Allworth Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.